The cholinergic hypothesis of Alzheimer’s disease: a review of progress

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  1999-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jnnp.66.2.137PMID 10071091PMCID PMC1736202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change

  2017cited by this paper
• Physostigmine restores3H-acetylcholine efflux from Alzheimer brain slices to normal level

  2005cited by this paper
• Effects of cholinergic and non-cholinergic drugs on visual discrimination and delayed visual discrimination performance in rats

  2005cited by this paper
• Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG

  2005cited by this paper
• Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors?

  2005cited by this paper
• Scopolamine and the control of attention in humans

  2004cited by this paper
• β-Amyloid precursor protein isoforms show correlations with neurones but not with glia of demented subjects

  2004cited by this paper
• Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?

  1999cited by this paper
• The cholinergic hypothesis of Alzheimer's disease: a review of progress.

  1999cited by this paper
• Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020

  1998cited by this paper
• Violent behavior-associated with donepezil.

  1998cited by this paper
• Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease

  1998cited by this paper
• Clarithromycin-induced mania.

  1998cited by this paper
• Donepezil Improves Cognition and Global Function in Alzheimer Disease A 15-Week, Double-blind, Placebo-Controlled Study

  1998cited by this paper
• Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects.

  1998cited by this paper
• Metrifonate treatment of the cognitive deficits of Alzheimer's disease

  1998cited by this paper
• Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices.

  1998cited by this paper
• Metrifonate for Alzheimer's disease

  1998cited by this paper
• A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

  1998cited by this paper
• Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

  1998cited by this paper
• Amyloid β‐Peptide Inhibits High‐Affinity Choline Uptake and Acetylcholine Release in Rat Hippocampal Slices

  1998cited by this paper
• Three-Month Sustained-Release Form of Triptorelin in Patients with Advanced Prostatic Adenocarcinoma: Results of an Open Pharmacodynamic and Pharmacokinetic Multicenter Study

  1998cited by this paper
• The Physiology and Pharmacology of Melatonin in Humans

  1998cited by this paper
• The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease.

  1998cited by this paper
• Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.

  1998cited by this paper
• β-Amyloid peptides as direct cholinergic neuromodulators: a missing link?

  1998cited by this paper
• Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study.

  1997cited by this paper
• Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

  1997cited by this paper
• Guidelines on drug treatments for Alzheimer's disease.

  1997cited by this paper
• The basis for behavioural disturbances in dementia.

  1997cited by this paper
• Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)

  1997cited by this paper
• Presynaptic Serotonergic Markers in Community‐Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication

  1996cited by this paper
• Neurochemical correlates of dementia.

  1996cited by this paper
• Effects of MF‐268, a new cholinesterase inhibitor, on acetylcholine and biogenic amines in rat cortex

  1996cited by this paper
• Structural correlates of cognition in dementia: quantification and assessment of synapse change.

  1996cited by this paper
• The basis for behavioural disturbances in dementia.

  1996cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

  1996cited by this paper
• Cholinesterase inhibition in Parkinson's disease.

  1996cited by this paper
• Activation of m1 Muscarinic Acetylcholine Receptor Regulates τ Phosphorylation in Transfected PC12 Cells

  1996cited by this paper
• From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease.

  1996cited by this paper
• Neuropsychiatric aspects of Alzheimer's disease

  1996cited by this paper
• Long-term tacrine (Cognex) treatment

  1996cited by this paper
• Galanthamine

  1996cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial

  1996cited by this paper
• Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease.

  1996cited by this paper
• Pyramidal nerve cell loss in Alzheimer's disease.

  1996cited by this paper
• Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020).

  1995cited by this paper
• Clinical heterogeneity: responders to cholinergic therapy.

  1995cited by this paper
• Cholinomimetics Increase Glutamate Outflow via an Action on the Corticostriatal Pathway: Implications for Alzheimer's Disease

  1995cited by this paper
• Changes in cortical nicotinic acetylcholine receptor numbers following unilateral destruction of pyramidal neurones by intrastriatal volkensin injection.

  1995cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology Confirmation of the Clinical Diagnosis of Alzheimer's Disease

  1995cited by this paper
• Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron

  1995cited by this paper
• Thyroid autoimmunity and ageing.

  1995cited by this paper
• Dissociation between cognitive and motor/motivational deficits in the delayed matching to position test: effects of scopolamine, 8-OH-DPAT and EAA antagonists

  1995cited by this paper
• Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds.

  1995cited by this paper
• A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease

  1994cited by this paper
• Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells.

  1994cited by this paper
• Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.

  1994cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1994cited by this paper
• Long-term use of tacrine.

  1994cited by this paper
• A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

  1994cited by this paper
• Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum

  1994cited by this paper
• Clinical-neuropathological correlations in Alzheimer's disease and related dementias.

  1994cited by this paper
• Nicotine and tetrahydroaminoacradine: Evidence for improved attention in patients with dementia of the Alzheimer type

  1994cited by this paper
• AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function

  1994cited by this paper
• Coupling of muscarinic receptors to GTP proteins in postmortem human brain--alterations in Alzheimer's disease.

  1993cited by this paper
• Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers.

  1993cited by this paper
• Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives

  1993cited by this paper
• Cholinergic control of cognitive resources.

  1993cited by this paper
• [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders].

  1993cited by this paper
• Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs.

  1993cited by this paper
• The Neurochemistry of Prion Diseases

  1993cited by this paper
• Clinical pharmacology of aminoacridines in Alzheimer's disease

  1993cited by this paper
• The cholinergic hypothesis of Alzheimer's disease

  1993cited by this paper
• Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia

  1992cited by this paper
• Pharmacological mechanisms and animal models of cognition.

  1992cited by this paper
• A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

  1992cited by this paper
• A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

  1992cited by this paper
• Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL).

  1992cited by this paper
• Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses

  1991cited by this paper
• The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions.

  1991cited by this paper
• Pharmacodynamics of Oral E2020 and Tacrine in Humans: Novel Approaches

  1991cited by this paper
• E2020 - THE PHARMACOLOGY OF A PIPERIDINE CHOLINESTERASE INHIBITOR

  1991cited by this paper
• The Second Generation of Cholinesterase Inhibitors: Clinical and Pharmacological Effects

  1991cited by this paper
• The cholinesterases.

  1991cited by this paper
• In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers.

  1991cited by this paper
• Effect of Central Cholinergic Stimulation on Regional Cerebral Blood Flow in Alzheimer's Disease

  1991cited by this paper
• Amyloid deposition as the central event in the aetiology of Alzheimer's disease.

  1991cited by this paper
• Cholinergic Basis for Alzheimer Therapy

  1991cited by this paper
• Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease.

  1990cited by this paper
• Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?

  1990cited by this paper
• Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

  1990cited by this paper
• Reversibility of the inhibition of acetylcholinesterase by tacrine.

  1990cited by this paper
• Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease.

  1990cited by this paper
• Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia

  1990cited by this paper
• Non‐Alzheimer‐type pattern of brain cholineacetyltransferase reduction in dominantly inherited olivopontocerebellar atrophy

  1989cited by this paper
• The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro

  1989cited by this paper
• Selective fimbria lesions impair acquisition of working and reference memory of rats in a complex spatial discrimination task.

  1989cited by this paper
• Possible neurotransmitter basis of behavioral changes in alzheimer's disease

  1988cited by this paper
• Interaction of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro.

  1988cited by this paper

• Early-Stage Corticostriatal Circuit Hyperactivity Impairs Cholinergic Function and Cognitive Flexibility in an Alzheimer’s Model

  2026cites this paper
• Standardized Hericium erinaceus Extract Powder Improves Scopolamine-Induced Cognitive Deficits via BDNF-Mediated Neuroplasticity

  2026cites this paper
• Pinoresinol diglucoside mitigates streptozotocin-induced cognitive decline in rats by regulating neurotransmitters, apoptosis and cytokines- NF-κB/ BDNF/ CREB/ caspase-3 pathway: Molecular docking study

  2026cites this paper
• Unraveling the Anti-Alzheimer's mechanisms of optimal constituent from Arisaema heterophyllum Blume through multi-model and phytochemical analysis.

  2026cites this paper
• Alzheimer’s Disease and Contemporary Therapeutic Approaches: Recent Advances in Natural Products

  2026cites this paper
• Structure‐Based In Silico Assessment of Strategically Designed Quinazolinone Derivatives for Multi‐Target Alzheimer's Disease: From ADMET to Molecular Dynamics

  2026cites this paper
• Synthesis and Biological Evaluations of the 1,3,5‐Triazine Derivatives as Cholinesterase Inhibitors, Antioxidant, and Biometal Chelators for Alzheimer's Disease

  2026cites this paper
• Advances in 1,3,4-thiadiazole-based cholinesterase inhibitors: toward novel therapeutics for Alzheimer's disease.

  2026cites this paper
• An Integrated QSAR-MD-DCCM Pipeline: A Predictive Computational Platform for the Rational Design and Dynamic Functional Validation of Dual-Target Directed Ligands.

  2026cites this paper
• α-Conotoxin LvID, an antagonist of α7 nicotinic acetylcholine receptor, mitigates Alzheimer-associated phenotypes by inhibiting Aβ deposition and reactive astrogliosis.

  2026cites this paper
• Multi-target approach to Alzheimer’s disease prevention and treatment: antioxidant, anti-inflammatory, and amyloid- modulating mechanisms

  2025cites this paper
• Enhanced in silico QSAR-based screening of butyrylcholinesterase inhibitors using multi-feature selection and machine learning

  2025cites this paper
• Use of Drugs Affecting GABAA Receptors and the Risk of Developing Alzheimer’s Disease and Dementia: a Meta-Analysis and Literature Review

  2025cites this paper
• Teucrium Polium ameliorates amyloid β-induced brain network disorders in rats: electrophysiological and behavioral studies

  2025cites this paper
• Dynamic analysis of hippocampal tripartite synapse model under acetylcholine deficiency related to Alzheimer's disease

  2025cites this paper
• Water-Soluble Ginseng Oligosaccharides Prevent Scopolamine-Induced Cholinergic Dysfunction and Inflammatory Cytokine Overexpression

  2025cites this paper
• New series of aromatic amides hybrids derivatives as anti-Alzheimer's drugs: Design, synthesis, biological activity and computational studies

  2025cites this paper
• REDEFINING ALZHEIMER’S DISEASE THROUGH MODERN BIOTECHNOLOGY; FROM MOLECULAR PATHOGENESIS TO INNOVATIVE THERAPEUTICS AND DIAGNOSTIC FRONTIERS

  2025cites this paper
• Design, synthesis, and computational insights into 3-acetyl-8-methoxy coumarin hybrids as potential anti-alzheimer’s agents

  2025cites this paper
• Biophysical analysis of angiotensin II and amyloid‐β cross‐interaction in aggregation and membrane disruption

  2025cites this paper
• Multi-omics dissection of SNP-mediated immunometabolic signatures in Alzheimer’s disease reveals a novel individual predictive model

  2025cites this paper
• Chronobiology and Neurodegeneration: The Role of Melatonin in Alzheimer's Disease

  2025cites this paper
• Associations Between Diabetes Mellitus and Neurodegenerative Diseases

  2025cites this paper
• Association between L-α glycerylphosphorylcholine use and delayed dementia conversion: A nationwide longitudinal study in South Korea

  2025cites this paper
• The complex interplay between ligand strain, coulombic interactions, and binding site dynamics of two congeneric AChE inhibitors

  2025cites this paper
• Microbial Trojan Horses: Virulence Factors as Key Players in Neurodegenerative Diseases

  2025cites this paper
• In Vitro Protective Effects of Resveratrol-Loaded Pluronic Micelles Against Hydrogen Peroxide-Induced Oxidative Damage in U87MG Glioblastoma Cells

  2025cites this paper
• Long-term nucleus basalis cholinergic lesions alter the structure of cortical vasculature, astrocytic density and microglial activity in Wistar rats.

  2025cites this paper
• Binding interaction of acetylcholinesterase with steroidal pregnanes: insight from machine learning and atomistic simulation.

  2025cites this paper
• Flavonoids and their role in oxidative stress, inflammation, and human diseases.

  2025cites this paper
• Exploring Alzheimer’s diseases with focus on diagnostic strategies targeting amyloid beta 42 (Aβ42)

  2025cites this paper
• Nutritional Value and Memory‐Improving Effects of Seven Major Nuts: A Comprehensive Study Using Network Pharmacology and In Vivo Assays

  2025cites this paper
• Gender‐Specific Neuroprotective Effects of Carum copticum and Thymol: Restoring Cholinergic Function and Cognition in an Aluminum‐Induced Rat Model of Alzheimer's Disease

  2025cites this paper
• Design, Synthesis, and Evaluation of 1-Benzylpiperidine and 1-Benzoylpiperidine Derivatives as Dual-Target Inhibitors of Acetylcholinesterase and Serotonin Transporter for Alzheimer′s Disease

  2025cites this paper
• Synthetic microneurotrophins: Neurotrophin receptors for therapeutics of neurodegenerative diseases

  2025cites this paper
• Hypericum empetrifolium subsp. empetrifolium: an assessment of its antifungal, antidiabetic, anti-aging, and neuroprotective potential.

  2025cites this paper
• Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease: Evidence, ARIA Risk, and Precision Patient Selection

  2025cites this paper
• Measuring phase-amplitude coupling using dispersion fuzzy mutual information

  2025cites this paper
• An appraisal on biomolecular imaging in diagnosis of neurological disorders and innovation in clinical research

  2025cites this paper
• In vitro anticholinesterase activities, molecular docking studies, DFT calculations and drug-likeness characters of β-keto ester

  2025cites this paper
• Multitarget-Directed Ligands for Alzheimer’s Disease: Recent Novel MTDLs and Mechanistic Insights

  2025cites this paper
• Measuring mild cognitive impairment whole-brain electroencephalography phase-amplitude coupling connectivity using polar mutual information

  2025cites this paper
• Synthesis, biological evaluation, and in silico studies of pyridoxal-amiridine hybrids as multitargeting anti-Alzheimer's disease agents.

  2025cites this paper
• Molecular Crossroads: Shared and Divergent Molecular Signatures in Alzheimer’s Disease and Dementia with Lewy Bodies

  2025cites this paper
• The therapeutic potential of beta-carotene against neuroinflammation and amyloid beta in SH-SY5Y cells

  2025cites this paper
• Neuroprotective Properties of Wild Mango (Mangifera caloneura Kurz) Leaves on Alleviating Urban Air Pollutant Toxicity: Insights From Transcriptome Analysis of a Human Neuronal Cell Model

  2025cites this paper
• Dietary Choline Intake and Risk of Alzheimer's Dementia in Older Adults.

  2025cites this paper
• Memory Enhancing Effects of Gastrodia elata Extract in a Scopolamine-Induced Memory Deficit Model

  2025cites this paper
• The orexin/hypocretin system in dementia-related neurological disorders: a double-edged sword in cognitive impairment

  2025cites this paper
• In vitro and in vivo Investigations of 4-Substituted 2-Phenylquinazoline derivatives as multipotent ligands for the treatment of Alzheimer's disease.

  2025cites this paper
• TeMac™ ameliorates memory impairment and cholinergic dysfunction in rats induced by scopolamine

  2025cites this paper
• Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy

  2025cites this paper
• Lycopodiaceae herb from Vietnam as a promising medicinal source of natural hupezine and novel huperzine-producing endophytic fungi

  2025cites this paper
• CNEURO-201, an Anti-amyloidogenic Agent and σ1-Receptor Agonist, Improves Cognition in the 3xTg Mouse Model of Alzheimer’s Disease by Multiple Actions in the Pathology

  2025cites this paper
• Stilbenes Against Alzheimer’s Disease: A Comprehensive Review of Preclinical Studies of Natural and Synthetic Compounds Combined with the Contributions of Developed Nanodrug Delivery Systems

  2025cites this paper
• Preclinical Alzheimer's disease shows alterations in circulating neuronal‐derived extracellular vesicle microRNAs in a multiethnic cohort

  2025cites this paper
• Development, biological evaluation, and molecular modelling of novel isocytosine and guanidine derivatives as BACE1 inhibitors using a fragment growing strategy.

  2025cites this paper
• Genetically encoded sensors illuminate in vivo detection for neurotransmission: Development, application, and optimization strategies

  2025cites this paper
• Design, Synthesis, and Anti-Alzheimer Activity of 2,5-Disubstituted 1,3,4-Thiadiazole: Kinetic Studies, Molecular Docking, and MD Simulations

  2025cites this paper
• Innovative approaches in acetylcholinesterase inhibition: a pathway to effective Alzheimer’s disease treatment

  2025cites this paper
• Role of Pyrazole Moiety in the Treatment of Alzheimer's Disease: A Comprehensive Review of Various Synthetic Routes and Probable Mechanisms of Action

  2025cites this paper
• Exploring Chalcone Derivatives as a Multifunctional Therapeutic Agent: Investigating Antioxidant Potential, Acetylcholinesterase Inhibition and Computational Insights

  2025cites this paper
• Structural changes to the basal forebrain cholinergic system in the continuum of Alzheimer disease.

  2025cites this paper
• Spatiotemporal patterns and optimal control in a diffusive Alzheimer's disease model with pharmacokinetics

  2025cites this paper
• In Silico Pharmacological and Pharmacokinetic Study of Marmeline From Bael Fruit for the Treatment of Alzheimer’s Disease

  2025cites this paper
• Structures and functions of the MICOS: Pathogenesis and therapeutic implications in Alzheimer's disease

  2025cites this paper
• CNS muscarinic receptors and muscarinic receptor agonists in Alzheimer disease treatment.

  2025cites this paper
• Computational Identification And Evaluation Of Potential BACE1 Inhibitors For Alzheimer's Disease Via Molecular Docking And Dynamics Simulations

  2025cites this paper
• From genetic roots to recent advancements in gene therapy targeting amyloid beta in Alzheimer’s disease

  2025cites this paper
• Expanding the role of alpha lipoic acid for psychiatric and neurological health

  2025cites this paper
• Sex-Stratified Transcriptomic Meta-Analysis of Alzheimer’s Disease Reveal Brain Region and Sex Specific Dysregulation

  2025cites this paper
• A Multi‐Analytical Exploration of Flavored Black Teas: Profiling Volatile Compounds, Caffeine Content, and Biological Effects

  2025cites this paper
• Neuroprotective Effects of Metformin Through the Modulation of Neuroinflammation and Oxidative Stress

  2025cites this paper
• Systemic medications and dementia risk: a systematic umbrella review

  2025cites this paper
• Human Glucose Transporters in Health and Selected Neurodegenerative Diseases

  2025cites this paper
• A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer’s disease

  2025cites this paper
• Unlocking ferulic acid for neurological diseases and tailoring of nanoformulations to advance its brain delivery.

  2025cites this paper
• Computational Insights into Dopamine-Mediated Conformational Transitions of Aβ Aggregates in Alzheimer's Disease.

  2025cites this paper
• The cholinergic basal forebrain and its role in neurodegeneration

  2025influential citation
• Anticholinergics, executive function, and cognitive/behavioral changes in Down syndrome

  2025cites this paper
• The Link Between Serum Levels of Dehydroepiandrosterone and Alzheimer’s Disease: A Pilot Study in the Serbian Population

  2025cites this paper
• Research progress on plant-derived natural compounds regulating the MAPK signaling pathway for the prevention and therapy of Alzheimer’s disease

  2025cites this paper
• The ameliorative effect of sodium butyrate alone or combined with vitamin E on oxidative stress and neurodegeneration in an experimental model of Alzheimer’s disease

  2025cites this paper
• Natural Products in Alzheimer’s Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms

  2025cites this paper
• Investigation of In vitro and In Silico Anticholinesterase Activities of Hydrazones Bearing 4-Iodobenzohydrazide Scaffolds

  2025cites this paper
• Design, Ssynthesis, and biological evaluation of β-secretase inhibitors: An integrated study of molecular docking, dynamics, pharmacokinetics, quantum chemistry, and in-vitro analysis for Alzheimer's disease.

  2025cites this paper
• Identifying Donepezil‐Like Compounds Against Acetylcholinesterase Using Molecular Docking, Dynamic Simulation, ADMET, and PCA: Therapeutic Management of Alzheimer’s Disease

  2025cites this paper
• The Pathological pathway for the Persistence of AD symptoms after the removal of amyloid plaques

  2025cites this paper
• Therapeutic and Safety Evaluation of Enhydra fluctuans Lour. and Ipomoea aquatica Forssk. as Acetylcholinesterase, Butyrylcholinesterase, β‐Secretase, and CytochromeP450 Inhibitors Using In Vitro and UPLC–QTOF–MS‐Based Molecular Docking and Dynamic Simulation Study

  2025cites this paper
• Amyloid Beta in Alzheimer's Disease: Mechanisms, Biomarker Potential, and Therapeutic Targets

  2025cites this paper
• Multi-Target-Directed Cinnamic Acid Hybrids Targeting Alzheimer’s Disease

  2024cites this paper
• Luteoloside inhibits Aβ1-42 fibrillogenesis, disintegrates preformed fibrils, and alleviates amyloid-induced cytotoxicity.

  2024cites this paper
• Characterizing fibril morphological changes by spirooxindoles for neurodegenerative disease application.

  2024cites this paper
• Assessing the potential of Psidium guajava derived phytoconstituents as anticholinesterase inhibitor to combat Alzheimer’s disease: an in-silico and in-vitro approach

  2024influential citation
• Öğrenme ve Bellek Deneylerinde Deney Hayvanlarına Yaklaşım ve Deney Modellerinin Değerlendirilmesi

  2024cites this paper
• Structure-based virtual screening of Trachyspermum ammi metabolites targeting acetylcholinesterase for Alzheimer’s disease treatment

  2024cites this paper
• "Cognitive enhancement and anti-oxidant activities of Thespesia populnea L.: A Bio-assay guided study using molecular docking for symptomatic alleviation of Alzheimer's disease"

  2024cites this paper
• Genetically Engineered Mouse Models for Alzheimer Disease and Frontotemporal Dementia: New Insights from Single-Cell and Spatial Transcriptomics.

  2024cites this paper
• Polyphenols and Their Biogenic Nano-Formulations Targeting BACE1 as Anti-Amyloid Therapies; Meeting the Challenges of Bioavailability, Safety, and Specificity for the Treatment of Alzheimer's Disease.

  2024cites this paper
• Exploring the Therapeutic Potential of Alkaloids in Alzheimer's Disease Management.

  2024cites this paper